Recommended Mix Momentum Stocks: Viacom (NASDAQ:VIAB), Harmonic (NASDAQ:HLIT)

Viacom, Inc. (NASDAQ:VIAB) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -9.40% to $34.99. National Amusements Inc., the owner of a majority of CBS Corp. (CBS) and ViacomInc.’s (VIAB) voting stock, declared on Monday that it has asked the Boards of CBS and Viacom to discontinue their exploration of a potential combination.Sumner Redstone and his daughter Shari Redstone’s National Amusement said that after reviewing a tie-up “we have concluded that this is not the right time to merge the companies.”

In late September, National Amusements said it believed a merger could “allow the combined company to respond even more aggressively and effectively to the challenges of the changing entertainment and media landscape.” The share price of VIAB attracts active investors, as stock price of week volatility recorded 3.84%. The stock is going forward to its 52-week low with 19.20% and lagging behind from its 52-week high price with -24.64%.

Harmonic Inc. (NASDAQ:HLIT) [Trend Analysis] moved down reacts as active mover, shares a loss -3.88% to traded at $4.95 and the percentage gap between open changing to regular change was -0.97%. Harmonic (NASDAQ:HLIT) declared that Ukrkosmos, the state-appointed operator of satellite telecommunications systems in Ukraine, has selected a Harmonic video compression solution to support its new teleport offering for direct-to-home (DTH) service delivery.

“Our new teleport service is unique to the marketplace, as it allows local DTH operators to use several satellites simultaneously, based on factors such as capacity and geographical location. To get the most out of the teleport’s bandwidth, we needed to partner with an expert in video compression solutions,” said Yuri Balychev, first deputy general director at Ukrkosmos.

“Harmonic’s Electra X2 media processor offers bandwidth efficiency, exceptional video quality and scalability giving our consumers the means to drive new revenue-generating services now and in the future.” The firm’s current ratio calculated as 1.60 for the most recent quarter. The firm past twelve months price to sales ratio was 1.01 and price to cash ratio remained 7.30. As far as the returns are concern, the return on equity was recorded as -22.80% and return on investment was -3.50% while its return on asset stayed at -12.10%. The firm has total debt to equity ratio measured as 0.44.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *